Text size :

Pharmaceuticals, Siviero (Farmindustria): “Payback main obstacle for the sector”

ADNKRONOS

November 9, 2026

Rome, Nov 9. (Adnkronos Health) – “If I had to indicate today the main obstacle to the competitiveness of the pharmaceutical sector in Italy, certainly one of the most characteristic elements is that related to payback, a system that has been in force for a long time now, but which today needs to be reformed, to be reviewed, also to allow innovation to be an integral part of the availability of therapeutic options for all citizens. Therefore, it is one of the elements on which to certainly work and it is also one of the signals on which the new budget law has begun to lay the foundations, so we are confident that we can continue to work in this direction”. Thus Paolo Siviero, Director of Access and Regulatory Strategies at Farmindustria, speaking at the event ‘The future of pharmaceutical legislation: a systemic vision’, organized by Nuove Reti in Rome.

“The Consolidated Law offers a great opportunity – he explains – to review some regulations, that of payback first and foremost, and the entire framework of the pharmaceutical system’s governance. In this, there is a need to move towards a greater link with the health outcomes that are produced. Therefore, a synergistic relationship between the benefits for the patient and the benefits for the system – he notes – This is one of the elements on which work can be done, on which the Consolidated Law can lay the foundations for future work, also thanks to the modernization of all data collection and utilization within the system”.

And precisely on modernization and the innovation connected to it, Siviero dwells: “Innovation is an essential cornerstone for the health of all citizens, it is also an essential cornerstone for a production system like the Italian one, which is absolutely one of the main leaders in Europe. We must ensure that it reaches patients and reaches the system as a whole”. For this to happen, on one hand, “a synergy between produced health outcomes and benefits for the system as a whole is needed, and on the other hand, there is a need for the ability to remain an attractive system also in terms of clinical experimentation and the system’s ability to welcome innovation,” he concludes.

Jiji Press

Related

Page TOP